Trial intelligence / Profile preview

Phase 3 study of maternal GBS6 vaccination in pregnant women and their infants

NL-OMON60324Phase 3Recruiting

Sponsor
Pfizer
Start
Mar 2026
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in Streptococcus agalactiae infection (GBS) comparing GBS6 with Placebo (2 arms). Primary endpoints: Prespecified local reactions, Prespecified systemic events and 5 more. Started Mar 2026; status: recruiting.

02

Drugs

GBS6
03

Conditions

Streptococcus agalactiae infection (GBS)

Beyond the preview

Go deeper on NL-OMON60324.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON60324.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call